Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand.
Identifieur interne : 003172 ( Main/Curation ); précédent : 003171; suivant : 003173Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand.
Auteurs : P R Little [Australie] ; A. Hodges ; T G Watson ; J A Seed ; S J MaederSource :
- New Zealand veterinary journal [ 0048-0169 ] ; 2010.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Anthelminthiques (usage thérapeutique), Association médicamenteuse (MeSH), Femelle (MeSH), Helminthoses animales (traitement médicamenteux), Helminthoses animales (épidémiologie), Ivermectine (administration et posologie), Ivermectine (analogues et dérivés), Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Maladies des ovins (parasitologie), Maladies des ovins (traitement médicamenteux), Maladies des ovins (épidémiologie), Mâle (MeSH), Nouvelle-Zélande (épidémiologie), Ovis (MeSH).
- MESH :
- administration et posologie : Ivermectine.
- analogues et dérivés : Ivermectine.
- effets indésirables : Ivermectine.
- parasitologie : Maladies des ovins.
- traitement médicamenteux : Helminthoses animales, Maladies des ovins.
- usage thérapeutique : Anthelminthiques, Ivermectine.
- épidémiologie : Helminthoses animales, Maladies des ovins, Nouvelle-Zélande.
- Animaux, Association médicamenteuse, Femelle, Mâle, Ovis.
English descriptors
- KwdEn :
- Animals (MeSH), Anthelmintics (therapeutic use), Drug Combinations (MeSH), Female (MeSH), Helminthiasis, Animal (drug therapy), Helminthiasis, Animal (epidemiology), Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (analogs & derivatives), Ivermectin (therapeutic use), Male (MeSH), New Zealand (epidemiology), Sheep (MeSH), Sheep Diseases (drug therapy), Sheep Diseases (epidemiology), Sheep Diseases (parasitology).
- MESH :
- chemical , administration & dosage : Ivermectin.
- chemical , adverse effects : Ivermectin.
- chemical , analogs & derivatives : Ivermectin.
- chemical , therapeutic use : Anthelmintics, Ivermectin.
- drug therapy : Helminthiasis, Animal, Sheep Diseases.
- epidemiology : Helminthiasis, Animal, New Zealand, Sheep Diseases.
- parasitology : Sheep Diseases.
- Animals, Drug Combinations, Female, Male, Sheep.
Abstract
AIM
To evaluate the efficacy and safety of the novel anthelmintic combination, derquantel-abamectin, against gastrointestinal nematode populations in sheep, under field-use conditions.
METHODS
Controlled faecal egg count reduction tests (FECRT) were conducted in New Zealand in 14 trials, covering a range of geographic locations, farming enterprises, breeds, nematode populations, and anthelmintic-resistance profiles. Enrolled animals were naturally infected with mixed populations of gastrointestinal nematodes. All trials included a group treated with derquantel-abamectin, and a negative control group. Nine trials included additional groups each treated with a single- or dual-active oral reference anthelmintic, selected from albendazole, levamisole, albendazole-levamisole, ivermectin, abamectin and moxidectin. A total of 838 animals were enrolled across all trials, and were randomly allocated to treatment groups within blocks defined by faecal nematode egg counts (FEC) pretreatment. On Day 0 derquantel-abamectin was administered orally at 1 ml/5 kg bodyweight (2 mg/kg derquantel, 0.2 mg/ kg abamectin), and each reference anthelmintic was given at the recommended label dose. Faecal samples were collected on Day 14 (+/- 1 day), to determine the percentage reduction in mean FEC for each anthelmintic tested. Larval differentiation was also performed post-treatment, to estimate efficacy at the genus level. Animals were weighed on or before Day 0, and on Day 14 (+/- 1 day) in 13 trials.
RESULTS
The efficacy of derquantel-abamectin against mixed strongyle populations was > or =99.2%, based on the percentage reduction in geometric mean FEC. Nematodirus sp. was present in six trials at a level sufficient for efficacy calculations to be conducted; in all cases, the efficacy of derquantel-abamectin was 100%. In those trials where the efficacy of at least one reference anthelmintic was <95% against strongyles and/or Nematodirus sp., derquantel-abamectin was 100% effective. In five trials, the mean gain in bodyweight was significantly greater in the derquantel- abamectin group than the negative controls.
CONCLUSIONS AND CLINICAL RELEVANCE
When administered orally at 1 ml/5 kg bodyweight, derquantel-abamectin is highly effective for the treatment of gastrointestinal nematodes in sheep, including populations of strongyles and Nematodirus sp. with resistance to one or more single- or dual-active anthelmintics. Derquantel-abamectin presents sheep producers with a unique opportunity to introduce a new class of anthelmintic to their nematode control programmes, with the added benefits offered by a combination anthelmintic.
DOI: 10.1080/00480169.2010.67513
PubMed: 20514085
PubMed Central: PMC3082775
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003172
Links to Exploration step
pubmed:20514085Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand.</title><author><name sortKey="Little, P R" sort="Little, P R" uniqKey="Little P" first="P R" last="Little">P R Little</name><affiliation wicri:level="1"><nlm:affiliation>Veterinary Medicine Research & Development, Pfizer Animal Health, 45 Poplar Road, Parkville 3052, Australia. peter.little@pfizer.com</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Veterinary Medicine Research & Development, Pfizer Animal Health, 45 Poplar Road, Parkville 3052</wicri:regionArea></affiliation></author><author><name sortKey="Hodges, A" sort="Hodges, A" uniqKey="Hodges A" first="A" last="Hodges">A. Hodges</name></author><author><name sortKey="Watson, T G" sort="Watson, T G" uniqKey="Watson T" first="T G" last="Watson">T G Watson</name></author><author><name sortKey="Seed, J A" sort="Seed, J A" uniqKey="Seed J" first="J A" last="Seed">J A Seed</name></author><author><name sortKey="Maeder, S J" sort="Maeder, S J" uniqKey="Maeder S" first="S J" last="Maeder">S J Maeder</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20514085</idno><idno type="pmid">20514085</idno><idno type="doi">10.1080/00480169.2010.67513</idno><idno type="pmc">PMC3082775</idno><idno type="wicri:Area/Main/Corpus">003172</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003172</idno><idno type="wicri:Area/Main/Curation">003172</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003172</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand.</title><author><name sortKey="Little, P R" sort="Little, P R" uniqKey="Little P" first="P R" last="Little">P R Little</name><affiliation wicri:level="1"><nlm:affiliation>Veterinary Medicine Research & Development, Pfizer Animal Health, 45 Poplar Road, Parkville 3052, Australia. peter.little@pfizer.com</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Veterinary Medicine Research & Development, Pfizer Animal Health, 45 Poplar Road, Parkville 3052</wicri:regionArea></affiliation></author><author><name sortKey="Hodges, A" sort="Hodges, A" uniqKey="Hodges A" first="A" last="Hodges">A. Hodges</name></author><author><name sortKey="Watson, T G" sort="Watson, T G" uniqKey="Watson T" first="T G" last="Watson">T G Watson</name></author><author><name sortKey="Seed, J A" sort="Seed, J A" uniqKey="Seed J" first="J A" last="Seed">J A Seed</name></author><author><name sortKey="Maeder, S J" sort="Maeder, S J" uniqKey="Maeder S" first="S J" last="Maeder">S J Maeder</name></author></analytic><series><title level="j">New Zealand veterinary journal</title><idno type="ISSN">0048-0169</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Anthelmintics (therapeutic use)</term><term>Drug Combinations (MeSH)</term><term>Female (MeSH)</term><term>Helminthiasis, Animal (drug therapy)</term><term>Helminthiasis, Animal (epidemiology)</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (analogs & derivatives)</term><term>Ivermectin (therapeutic use)</term><term>Male (MeSH)</term><term>New Zealand (epidemiology)</term><term>Sheep (MeSH)</term><term>Sheep Diseases (drug therapy)</term><term>Sheep Diseases (epidemiology)</term><term>Sheep Diseases (parasitology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Anthelminthiques (usage thérapeutique)</term><term>Association médicamenteuse (MeSH)</term><term>Femelle (MeSH)</term><term>Helminthoses animales (traitement médicamenteux)</term><term>Helminthoses animales (épidémiologie)</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (analogues et dérivés)</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Maladies des ovins (parasitologie)</term><term>Maladies des ovins (traitement médicamenteux)</term><term>Maladies des ovins (épidémiologie)</term><term>Mâle (MeSH)</term><term>Nouvelle-Zélande (épidémiologie)</term><term>Ovis (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Helminthiasis, Animal</term><term>Sheep Diseases</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Helminthiasis, Animal</term><term>New Zealand</term><term>Sheep Diseases</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Maladies des ovins</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Sheep Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Helminthoses animales</term><term>Maladies des ovins</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anthelminthiques</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Helminthoses animales</term><term>Maladies des ovins</term><term>Nouvelle-Zélande</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Combinations</term><term>Female</term><term>Male</term><term>Sheep</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association médicamenteuse</term><term>Femelle</term><term>Mâle</term><term>Ovis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>AIM</b></p><p>To evaluate the efficacy and safety of the novel anthelmintic combination, derquantel-abamectin, against gastrointestinal nematode populations in sheep, under field-use conditions.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Controlled faecal egg count reduction tests (FECRT) were conducted in New Zealand in 14 trials, covering a range of geographic locations, farming enterprises, breeds, nematode populations, and anthelmintic-resistance profiles. Enrolled animals were naturally infected with mixed populations of gastrointestinal nematodes. All trials included a group treated with derquantel-abamectin, and a negative control group. Nine trials included additional groups each treated with a single- or dual-active oral reference anthelmintic, selected from albendazole, levamisole, albendazole-levamisole, ivermectin, abamectin and moxidectin. A total of 838 animals were enrolled across all trials, and were randomly allocated to treatment groups within blocks defined by faecal nematode egg counts (FEC) pretreatment. On Day 0 derquantel-abamectin was administered orally at 1 ml/5 kg bodyweight (2 mg/kg derquantel, 0.2 mg/ kg abamectin), and each reference anthelmintic was given at the recommended label dose. Faecal samples were collected on Day 14 (+/- 1 day), to determine the percentage reduction in mean FEC for each anthelmintic tested. Larval differentiation was also performed post-treatment, to estimate efficacy at the genus level. Animals were weighed on or before Day 0, and on Day 14 (+/- 1 day) in 13 trials.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The efficacy of derquantel-abamectin against mixed strongyle populations was > or =99.2%, based on the percentage reduction in geometric mean FEC. Nematodirus sp. was present in six trials at a level sufficient for efficacy calculations to be conducted; in all cases, the efficacy of derquantel-abamectin was 100%. In those trials where the efficacy of at least one reference anthelmintic was <95% against strongyles and/or Nematodirus sp., derquantel-abamectin was 100% effective. In five trials, the mean gain in bodyweight was significantly greater in the derquantel- abamectin group than the negative controls.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS AND CLINICAL RELEVANCE</b></p><p>When administered orally at 1 ml/5 kg bodyweight, derquantel-abamectin is highly effective for the treatment of gastrointestinal nematodes in sheep, including populations of strongyles and Nematodirus sp. with resistance to one or more single- or dual-active anthelmintics. Derquantel-abamectin presents sheep producers with a unique opportunity to introduce a new class of anthelmintic to their nematode control programmes, with the added benefits offered by a combination anthelmintic.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20514085</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-0169</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>New Zealand veterinary journal</Title><ISOAbbreviation>N Z Vet J</ISOAbbreviation></Journal><ArticleTitle>Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand.</ArticleTitle><Pagination><MedlinePgn>121-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00480169.2010.67513</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of the novel anthelmintic combination, derquantel-abamectin, against gastrointestinal nematode populations in sheep, under field-use conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Controlled faecal egg count reduction tests (FECRT) were conducted in New Zealand in 14 trials, covering a range of geographic locations, farming enterprises, breeds, nematode populations, and anthelmintic-resistance profiles. Enrolled animals were naturally infected with mixed populations of gastrointestinal nematodes. All trials included a group treated with derquantel-abamectin, and a negative control group. Nine trials included additional groups each treated with a single- or dual-active oral reference anthelmintic, selected from albendazole, levamisole, albendazole-levamisole, ivermectin, abamectin and moxidectin. A total of 838 animals were enrolled across all trials, and were randomly allocated to treatment groups within blocks defined by faecal nematode egg counts (FEC) pretreatment. On Day 0 derquantel-abamectin was administered orally at 1 ml/5 kg bodyweight (2 mg/kg derquantel, 0.2 mg/ kg abamectin), and each reference anthelmintic was given at the recommended label dose. Faecal samples were collected on Day 14 (+/- 1 day), to determine the percentage reduction in mean FEC for each anthelmintic tested. Larval differentiation was also performed post-treatment, to estimate efficacy at the genus level. Animals were weighed on or before Day 0, and on Day 14 (+/- 1 day) in 13 trials.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The efficacy of derquantel-abamectin against mixed strongyle populations was > or =99.2%, based on the percentage reduction in geometric mean FEC. Nematodirus sp. was present in six trials at a level sufficient for efficacy calculations to be conducted; in all cases, the efficacy of derquantel-abamectin was 100%. In those trials where the efficacy of at least one reference anthelmintic was <95% against strongyles and/or Nematodirus sp., derquantel-abamectin was 100% effective. In five trials, the mean gain in bodyweight was significantly greater in the derquantel- abamectin group than the negative controls.</AbstractText><AbstractText Label="CONCLUSIONS AND CLINICAL RELEVANCE" NlmCategory="CONCLUSIONS">When administered orally at 1 ml/5 kg bodyweight, derquantel-abamectin is highly effective for the treatment of gastrointestinal nematodes in sheep, including populations of strongyles and Nematodirus sp. with resistance to one or more single- or dual-active anthelmintics. Derquantel-abamectin presents sheep producers with a unique opportunity to introduce a new class of anthelmintic to their nematode control programmes, with the added benefits offered by a combination anthelmintic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Little</LastName><ForeName>P R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Veterinary Medicine Research & Development, Pfizer Animal Health, 45 Poplar Road, Parkville 3052, Australia. peter.little@pfizer.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>T G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Seed</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Maeder</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>N Z Vet J</MedlineTA><NlmUniqueID>0021406</NlmUniqueID><ISSNLinking>0048-0169</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>5U8924T11H</RegistryNumber><NameOfSubstance UI="C048324">abamectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006374" MajorTopicYN="N">Helminthiasis, Animal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N">New Zealand</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012756" MajorTopicYN="N">Sheep</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012757" MajorTopicYN="N">Sheep Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20514085</ArticleId><ArticleId IdType="doi">10.1080/00480169.2010.67513</ArticleId><ArticleId IdType="pmc">PMC3082775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aust Vet J. 2003 Jun;81(6):359-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15080459</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 2009 Apr 6;161(1-2):162-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19135802</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Rec. 2005 Jan 22;156(4):105-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15704550</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 1990 Jun;38(2):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16031574</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Rec. 2003 Nov 8;153(19):604</Citation><ArticleIdList><ArticleId IdType="pubmed">14640331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Parasitol. 1990 Jun;76(3):349-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2352063</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2009 Aug;57(4):181-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19649011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2001 Feb 26;11(4):553-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11229769</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 1996 Apr;44(2):73-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16031898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Mar 13;452(7184):176-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18337814</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2006 Dec;54(6):323-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17151732</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2006 Dec;54(6):271-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17151724</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Vet J. 1991 Apr;68(4):127-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2069539</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 1999 Mar 1;81(3):211-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10190865</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2008 Apr;56(2):67-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18408792</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Parasitol. 1990 Nov;20(7):913-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2276866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vet Pharmacol Ther. 2004 Jun;27(3):169-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15189303</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Vet J. 2001 Dec;79(12):840-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11837906</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasitol Today. 1995 Feb;11(2):56-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15275374</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2009 Feb;57(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19252536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Rec. 2007 Jul 7;161(1):36</Citation><ArticleIdList><ArticleId IdType="pubmed">17617547</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Vet J. 1991 Apr;68(4):133-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2069540</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2007 Aug;55(4):177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17676082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2008 May 1;18(9):2935-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18400497</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Rec. 1997 Nov 1;141(18):472-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9392066</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2006 Nov 25;79(26):2413-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16979192</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Parasitol. 2007 Jan;23(1):21-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17118708</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Vet J. 2001 Nov;79(11):756-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11789911</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Vet J. 1988 Feb;65(2):66-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3355458</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 2001 Apr 2;96(3):171-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11240092</ArticleId></ArticleIdList></Reference><Reference><Citation>Onderstepoort J Vet Res. 1999 Dec;66(4):273-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 2006 Mar 31;136(3-4):167-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16427201</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 1997 Dec;45(6):244-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16031998</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust Vet J. 1988 Feb;65(2):62-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3355455</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Vet J. 2006 Feb;54(1):47-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16528395</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 2005 Dec 10;134(3-4):261-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16168563</ArticleId></ArticleIdList></Reference><Reference><Citation>Onderstepoort J Vet Res. 1989 Mar;56(1):41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2726192</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 2007 Apr 10;145(1-2):65-76</Citation><ArticleIdList><ArticleId IdType="pubmed">17134836</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Med Chem. 2002 Jul;2(7):779-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12052190</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Parasitol. 1995 Jun;58(3):181-213</Citation><ArticleIdList><ArticleId IdType="pubmed">7571325</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Parasitol. 2004 Oct;20(10):477-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15363441</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003172 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003172 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:20514085
|texte= Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:20514085" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |